

Special Issue

Advancements in Lung Cancer Surgical Treatment and Prognosis

Message from the Guest Editors

Lung cancer, a leading cause of cancer-related mortality worldwide, is on the cusp of a transformative era. With advancements in surgical techniques, targeted therapies, and the emergence of immunotherapies, our approach to combating this disease is evolving. Key factors include accurate staging, early biomarker detection, and insights from recent clinical trials, all shaping the future of cancer outcomes. This Special Issue will highlight the latest developments in lung cancer treatment. The aim is to explore the newest surgical techniques, prognosis, and the role of targeted and immunotherapies, and to engage in discussions that are changing the landscape of lung cancer care. We are seeking insightful manuscripts that explore the forefront of lung cancer surgical techniques, the impact of targeted therapies, and the collaborative dialogues steering lung cancer care. Contributions that illuminate the nuances of precise staging, the critical importance of early molecular testing, and findings from contemporary clinical trials are particularly sought after.

Guest Editors

Prof. Dr. Sai Yendamuri

Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA

Dr. Kenneth Patrick Seastedt

Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA

Deadline for manuscript submissions

15 August 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/183467

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)